264 related articles for article (PubMed ID: 23164197)
1. Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.
Fautrel B; Granger B; Combe B; Saraux A; Guillemin F; Le Loet X
Arthritis Res Ther; 2012 Nov; 14(6):R249. PubMed ID: 23164197
[TBL] [Abstract][Full Text] [Related]
2. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
[TBL] [Abstract][Full Text] [Related]
3. An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases.
Vanier A; Smolen JS; Allaart CF; Van Vollenhoven R; Verschueren P; Vastesaeger N; Saevarsdottir S; Visser K; Aletaha D; Combe B; Fautrel B
Rheumatology (Oxford); 2020 Aug; 59(8):1842-1852. PubMed ID: 31722413
[TBL] [Abstract][Full Text] [Related]
4. Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data.
Granger B; Combe B; Le Loet X; Saraux A; Guillemin F; Fautrel B
RMD Open; 2016; 2(1):e000245. PubMed ID: 27252898
[TBL] [Abstract][Full Text] [Related]
5. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
[TBL] [Abstract][Full Text] [Related]
6. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study.
Visser K; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Ronday HK; Seys PE; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2010 Jul; 69(7):1333-7. PubMed ID: 20498212
[TBL] [Abstract][Full Text] [Related]
7. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.
Vastesaeger N; Xu S; Aletaha D; St Clair EW; Smolen JS
Rheumatology (Oxford); 2009 Sep; 48(9):1114-21. PubMed ID: 19589891
[TBL] [Abstract][Full Text] [Related]
8. Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis.
Rydell E; Forslind K; Nilsson JÅ; Jacobsson LTH; Turesson C
Arthritis Res Ther; 2018 May; 20(1):82. PubMed ID: 29720260
[TBL] [Abstract][Full Text] [Related]
9. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.
Ellingsen T; Hansen I; Thorsen J; Møller BK; Tarp U; Lottenburger T; Andersen LS; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Lindegaard H; Jacobsen S; Østergaard M; Vestergaard A; Jurik AG; Junker P; Christensen AF; Hetland ML; Hørslev-Petersen K; Stengaard-Pedersen K
Scand J Rheumatol; 2014; 43(2):91-100. PubMed ID: 23980529
[TBL] [Abstract][Full Text] [Related]
10. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.
van Nies JA; Tsonaka R; Gaujoux-Viala C; Fautrel B; van der Helm-van Mil AH
Ann Rheum Dis; 2015 May; 74(5):806-12. PubMed ID: 25561360
[TBL] [Abstract][Full Text] [Related]
11. Can we prevent rapid radiological progression in patients with early rheumatoid arthritis?
Heimans L; Wevers-deBoer KV; Ronday HK; Collée G; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
Clin Rheumatol; 2015 Jan; 34(1):163-6. PubMed ID: 25431327
[TBL] [Abstract][Full Text] [Related]
12. Assessing the risk of rapid radiographic progression in Hungarian rheumatoid arthritis patients.
Végh E; Gaál J; Géher P; Gömöri E; Kovács A; Kovács L; Nagy K; Posta EF; Tamási L; Tóth E; Varga E; Domján A; Szekanecz Z; Szűcs G
BMC Musculoskelet Disord; 2021 Apr; 22(1):325. PubMed ID: 33794855
[TBL] [Abstract][Full Text] [Related]
13. The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database.
Scott DL; Strand V
Rheumatology (Oxford); 2002 Aug; 41(8):899-909. PubMed ID: 12154207
[TBL] [Abstract][Full Text] [Related]
14. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P
Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044
[TBL] [Abstract][Full Text] [Related]
15. Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis.
Lillegraven S; Paynter N; Prince FH; Shadick NA; Haavardsholm EA; Frits ML; Iannaccone CK; Kvien TK; Weinblatt ME; Solomon DH
Arthritis Care Res (Hoboken); 2013 Apr; 65(4):526-33. PubMed ID: 23044765
[TBL] [Abstract][Full Text] [Related]
16. MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial.
Yu X; Zhang L; Wang L; Lu W; Sun F; Xu P; Lan G
Clin Rheumatol; 2018 Apr; 37(4):917-925. PubMed ID: 29313271
[TBL] [Abstract][Full Text] [Related]
17. Disease modification in rheumatoid arthritis with leflunomide.
Emery P
Scand J Rheumatol Suppl; 1999; 112():9-14. PubMed ID: 10668522
[TBL] [Abstract][Full Text] [Related]
18. Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis: results from a French multicenter cohort.
Vesperini V; Lukas C; Fautrel B; Le Loet X; Rincheval N; Combe B
Arthritis Care Res (Hoboken); 2013 Dec; 65(12):1899-906. PubMed ID: 23836776
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort.
Degboé Y; Constantin A; Nigon D; Tobon G; Cornillet M; Schaeverbeke T; Chiocchia G; Nicaise-Roland P; Nogueira L; Serre G; Cantagrel A; Ruyssen-Witrand A
RMD Open; 2015; 1(1):e000180. PubMed ID: 26635969
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions.
Castrejón I; Dougados M; Combe B; Fautrel B; Guillemin F; Pincus T
J Rheumatol; 2016 Jul; 43(7):1285-91. PubMed ID: 27084913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
